Compare Charles River Laboratories Intl. Inc (CRL) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Thomson Reuters Corp — how do they compare? Charles River Laboratories Intl. Inc trades at $231.21 (market cap $11.14B), while Thomson Reuters Corp trades at $91.64 (market cap $39.67B). The key difference: Thomson Reuters Corp is far larger — about 3.6× Charles River Laboratories Intl. Inc's market cap, and Thomson Reuters Corp pays a 2.86% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | TRI | |
|---|---|---|
Market Cap | $11.14B | $39.67B |
Sector | Health | Industrials |
52-Week High | $233.60 | $211.14 |
52-Week Low | $145.57 | $76.55 |
Enterprise Value | $14.00B | $41.62B |
Dividend Yield | — | 2.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Thomson Reuters (TRI) trades at $94.29, up 5.18% today, showing strong momentum near resistance at $95. The stock maintains solid fundamentals with a 19.93% net margin and has beaten earnings estimates in two of the last three quarters. Recent developments include a joint venture with KKR and continued AI integration, positioning the company for growth in legal and professional markets.
The outlook is positive with a consensus price target of $129.96 implying 38% upside, supported by bullish analyst ratings (52% Buy). Key risks include execution of AI strategies and potential revenue pressures from market shifts. Institutional confidence remains high given stable cash flows and strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
